|
Volumn 3, Issue 5, 2007, Pages 605-609
|
Aldosterone antagonism in heart failure
|
Author keywords
Aldosterone; Eplerenone; Heart failure
|
Indexed keywords
ALDOSTERONE;
ALDOSTERONE ANTAGONIST;
ANGIOTENSIN 1 RECEPTOR;
ANGIOTENSIN I;
ANGIOTENSIN II;
ANGIOTENSIN RECEPTOR ANTAGONIST;
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
DIGOXIN;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
ELECTROLYTE;
EPLERENONE;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
LOOP DIURETIC AGENT;
MINERALOCORTICOID RECEPTOR;
NEUROHORMONE;
NORADRENALIN;
PLACEBO;
SPIRONOLACTONE;
CLINICAL TRIAL;
CONGESTIVE HEART FAILURE;
COST BENEFIT ANALYSIS;
DRUG COST;
DRUG DOSE REDUCTION;
DRUG HALF LIFE;
DRUG POTENTIATION;
DRUG RECEPTOR BINDING;
DRUG WITHDRAWAL;
FIRST PASS EFFECT;
GYNECOMASTIA;
HEART EJECTION FRACTION;
HEART FAILURE;
HEART INFARCTION;
HORMONE INHIBITION;
HOSPITALIZATION;
HUMAN;
HYPERKALEMIA;
MONOTHERAPY;
MORTALITY;
PATHOPHYSIOLOGY;
PROTEIN SYNTHESIS INHIBITION;
RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;
REVIEW;
RISK REDUCTION;
SYMPTOMATOLOGY;
SYSTOLIC DYSFUNCTION;
TREATMENT OUTCOME;
ALDOSTERONE;
ALDOSTERONE ANTAGONISTS;
ANGIOTENSINS;
HEART FAILURE;
HUMANS;
|
EID: 36148947078
PISSN: 11766344
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
Times cited : (14)
|
References (9)
|